157 related articles for article (PubMed ID: 12431797)
41. Heterozygous gsp mutation renders ion channels of human somatotroph adenoma cells unresponsive to growth hormone-releasing hormone.
Yasufuku-Takano J; Takano K; Takei T; Fukumoto S; Teramoto A; Takakura K; Yamashita N; Fujita T
Endocrinology; 1999 May; 140(5):2018-26. PubMed ID: 10218950
[TBL] [Abstract][Full Text] [Related]
42. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
Morita K; Takano K; Yasufuku-Takano J; Yamada S; Teramoto A; Takei M; Osamura RY; Sano T; Fujita T
Clin Endocrinol (Oxf); 2008 Mar; 68(3):435-41. PubMed ID: 18070145
[TBL] [Abstract][Full Text] [Related]
43. Gs alpha mutations in hyperfunctioning thyroid adenomas.
Murakami M; Kamiya Y; Yanagita Y; Mori M
Arch Med Res; 1999; 30(6):514-21. PubMed ID: 10714366
[TBL] [Abstract][Full Text] [Related]
44. Pit-1 gene expression in human pituitary adenomas.
Pellegrini-Bouiller I; Morange-Ramos I; Barlier A; Gunz G; Enjalbert A; Jaquet P
Horm Res; 1997; 47(4-6):251-8. PubMed ID: 9167960
[TBL] [Abstract][Full Text] [Related]
45. Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels.
Hofland LJ; Velkeniers B; vd Lely AJ; van Koetsveld PM; Kazemzadeh M; Waaijers M; Hooghe-Peters EL; Lamberts SW
Clin Endocrinol (Oxf); 1992 Sep; 37(3):240-8. PubMed ID: 1424206
[TBL] [Abstract][Full Text] [Related]
46. Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors.
Bi WL; Greenwald NF; Ramkissoon SH; Abedalthagafi M; Coy SM; Ligon KL; Mei Y; MacConaill L; Ducar M; Min L; Santagata S; Kaiser UB; Beroukhim R; Laws ER; Dunn IF
Endocrinology; 2017 Jul; 158(7):2284-2291. PubMed ID: 28486603
[TBL] [Abstract][Full Text] [Related]
47. Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.
Ruebel KH; Leontovich AA; Jin L; Stilling GA; Zhang H; Qian X; Nakamura N; Scheithauer BW; Kovacs K; Lloyd RV
Endocrine; 2006 Jun; 29(3):435-44. PubMed ID: 16943582
[TBL] [Abstract][Full Text] [Related]
48. GSPalpha mutations in Mexican patients with acromegaly: potential impact on long term prognosis.
Mendoza V; Sosa E; Espinosa-de-Los-Monteros AL; Salcedo M; Guinto G; Cheng S; Sandoval C; Mercado M
Growth Horm IGF Res; 2005 Feb; 15(1):28-32. PubMed ID: 15701569
[TBL] [Abstract][Full Text] [Related]
49. The gsalpha gene: predominant maternal origin of transcription in human thyroid gland and gonads.
Mantovani G; Ballare E; Giammona E; Beck-Peccoz P; Spada A
J Clin Endocrinol Metab; 2002 Oct; 87(10):4736-40. PubMed ID: 12364467
[TBL] [Abstract][Full Text] [Related]
50. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
[TBL] [Abstract][Full Text] [Related]
51. Pituitary adenomas: screening for G alpha q mutations.
Oyesiku NM; Evans CO; Brown MR; Blevins LS; Tindall GT; Parks JS
J Clin Endocrinol Metab; 1997 Dec; 82(12):4184-8. PubMed ID: 9398737
[TBL] [Abstract][Full Text] [Related]
52. p53 gene mutations in pituitary adenomas: rare events.
Levy A; Hall L; Yeudall WA; Lightman SL
Clin Endocrinol (Oxf); 1994 Dec; 41(6):809-14. PubMed ID: 7889618
[TBL] [Abstract][Full Text] [Related]
53. Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomas.
Faccenda E; Melmed S; Bevan JS; Eidne KA
Clin Endocrinol (Oxf); 1996 Mar; 44(3):341-7. PubMed ID: 8729534
[TBL] [Abstract][Full Text] [Related]
54. Absence of mutations in the growth hormone (GH)-releasing hormone receptor gene in GH-secreting pituitary adenomas.
Salvatori R; Thakker RV; Lopes MB; Fan X; Eswara JR; Ellison D; Lees P; Harding B; Yang I; Levine MA
Clin Endocrinol (Oxf); 2001 Mar; 54(3):301-7. PubMed ID: 11298081
[TBL] [Abstract][Full Text] [Related]
55. The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas.
Ogino A; Yoshino A; Katayama Y; Watanabe T; Ota T; Komine C; Yokoyama T; Fukushima T
J Neuropathol Exp Neurol; 2005 May; 64(5):398-403. PubMed ID: 15892297
[TBL] [Abstract][Full Text] [Related]
56. Molecular screening of pituitary adenomas for gene mutations and rearrangements.
Herman V; Drazin NZ; Gonsky R; Melmed S
J Clin Endocrinol Metab; 1993 Jul; 77(1):50-5. PubMed ID: 8100831
[TBL] [Abstract][Full Text] [Related]
57. Activating mutations of the Gs alpha gene are associated with low levels of Gs alpha protein in growth hormone-secreting tumors.
Ballaré E; Mantovani S; Lania A; Di Blasio AM; Vallar L; Spada A
J Clin Endocrinol Metab; 1998 Dec; 83(12):4386-90. PubMed ID: 9851782
[TBL] [Abstract][Full Text] [Related]
58. The role of hormones, growth factors and their receptors in pituitary tumorigenesis.
Ezzat S
Brain Pathol; 2001 Jul; 11(3):356-70. PubMed ID: 11414477
[TBL] [Abstract][Full Text] [Related]
59. Identification of G protein alpha subunit mutations in human growth hormone (GH)- and GH/prolactin-secreting pituitary tumors by single-strand conformation polymorphism (SSCP) analysis.
Drews RT; Gravel RA; Collu R
Mol Cell Endocrinol; 1992 Sep; 87(1-3):125-9. PubMed ID: 1446784
[TBL] [Abstract][Full Text] [Related]
60. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
